179 related articles for article (PubMed ID: 29638111)
1. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
He MY; Li WK; Zheng QC; Zhang HX
ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
[TBL] [Abstract][Full Text] [Related]
2. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
3. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
4. Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.
Chen J; Wang W; Sun H; Pang L; Yin B
J Comput Aided Mol Des; 2020 Dec; 34(12):1289-1305. PubMed ID: 33073300
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
6. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations.
He MY; Li WK; Meiler J; Zheng QC; Zhang HX
Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
Tamirat MZ; Koivu M; Elenius K; Johnson MS
PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
[TBL] [Abstract][Full Text] [Related]
9. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.
Jiang CH; Huang CX; Chen YJ; Chuang YC; Huang BY; Yang CN
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004444
[TBL] [Abstract][Full Text] [Related]
10. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
11. Generation of induced pluripotent stem cell lines from two Neuroblastoma patients carrying a germline ALK R1275Q mutation.
Marin Navarro A; Day K; Kogner P; Wilhelm M; Falk A
Stem Cell Res; 2019 Jan; 34():101356. PubMed ID: 30605844
[TBL] [Abstract][Full Text] [Related]
12. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
Huang H; Gont A; Kee L; Dries R; Pfeifer K; Sharma B; Debruyne DN; Harlow M; Sengupta S; Guan J; Yeung CM; Wang W; Hallberg B; Palmer RH; Irwin MS; George RE
Cell Rep; 2021 Jul; 36(2):109363. PubMed ID: 34260934
[TBL] [Abstract][Full Text] [Related]
13. The ALK receptor in sympathetic neuron development and neuroblastoma.
Janoueix-Lerosey I; Lopez-Delisle L; Delattre O; Rohrer H
Cell Tissue Res; 2018 May; 372(2):325-337. PubMed ID: 29374774
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for ligand reception by anaplastic lymphoma kinase.
Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
[TBL] [Abstract][Full Text] [Related]
15. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
16. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
He M; Li W; Zheng Q; Zhang H
J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
[TBL] [Abstract][Full Text] [Related]
17. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
Wulf AM; Moreno MM; Paka C; Rampasekova A; Liu KJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769149
[TBL] [Abstract][Full Text] [Related]
18. Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation.
Guan J; Yamazaki Y; Chand D; van Dijk JR; Ruuth K; Palmer RH; Hallberg B
Cancers (Basel); 2017 Oct; 9(11):. PubMed ID: 29084134
[TBL] [Abstract][Full Text] [Related]
19. F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations.
Dehghanian F; Kay M; Vallian S
J Mol Graph Model; 2017 Aug; 75():287-293. PubMed ID: 28622610
[TBL] [Abstract][Full Text] [Related]
20. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]